| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w20532 |
| 来源ID | Working Paper 20532 |
| Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation | |
| Lee Branstetter; Chirantan Chatterjee; Matthew J. Higgins | |
| 发表日期 | 2014-09-25 |
| 出版年 | 2014 |
| 语种 | 英语 |
| 摘要 | What impact has rising generic competition had on the nature and direction of pharmaceutical innovation? We find broad-based, strong evidence that pharmaceutical companies have diverted their new drug development efforts away from therapeutic markets already well-served by generic drugs. We also find that increasing generic competition induces firms to shift their R&D activity towards more biologic-based products and away from chemical-based products. We conclude by discussing potential implications of our results for long-run innovation policy. |
| 主题 | Microeconomics ; Households and Firms ; Industrial Organization ; Regulatory Economics ; Industry Studies ; Other ; Accounting, Marketing, and Personnel |
| URL | https://www.nber.org/papers/w20532 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/578206 |
| 推荐引用方式 GB/T 7714 | Lee Branstetter,Chirantan Chatterjee,Matthew J. Higgins. Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation. 2014. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
